{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:45:39Z","timestamp":1782737139447,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Abbott"},{"name":"AstraZeneca"},{"DOI":"10.13039\/100015739","name":"Bayer Vital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015739","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim"},{"name":"Sanofi"},{"DOI":"10.13039\/501100010215","name":"German Diabetes Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010215","id-type":"DOI","asserted-by":"crossref"}]},{"name":"German Centre for Diabetes Research","award":["82DZD14E03"],"award-info":[{"award-number":["82DZD14E03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The FIDELIO-DKD and FIGARO-DKD randomized clinical trials (RCTs) showed finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), reduced the risk of renal and cardiovascular events in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Using RCT inclusion and exclusion criteria, we analyzed the RCT coverage for patients with T2DM and CKD in routine clinical practice in Germany.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>German patients from the DPV\/DIVE registries who were\u2009\u2265\u200918\u00a0years, had T2DM and CKD (an estimated glomerular filtration rate [eGFR]\u2009&lt;\u200960\u00a0mL\/min\/1.73 m<jats:sup>2<\/jats:sup><jats:italic>OR<\/jats:italic> eGFR\u2009\u2265\u200960\u00a0mL\/min\/1.73m<jats:sup>2<\/jats:sup> and albuminuria [\u2265\u200930\u00a0mg\/g]) were included. RCT inclusion and exclusion criteria were then applied, and the characteristics of the two populations compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 65,168 patients with T2DM and CKD were identified from DPV\/DIVE. Key findings were (1) Registry patients with CKD were older, less often male, and had a lower eGFR, but more were normoalbuminuric vs the RCTs. Cardiovascular disease burden was higher in the RCTs; diabetic neuropathy, lipid metabolism disorders, and peripheral arterial disease were more frequent in the registry. CKD-specific drugs (e.g., angiotensin-converting enzyme inhibitors [ACEi] and angiotensin receptor blocker [ARBs]) were used less often in clinical practice; (2) Due to the RCT\u2019s albuminuric G1\/2 to G4 CKD focus, they did not cover 28,147 (43.2%) normoalbuminuric registry patients, 4,519 (6.9%) albuminuric patients with eGFR\u2009&lt;\u200925, and 6,565 (10.1%) patients with microalbuminuria but normal GFR (\u2265\u200990\u00a0ml\/min); 3) As RCTs required baseline ACEi or ARB treatment, the number of comparable registry patients was reduced to 28,359. Of these, only 12,322 (43.5%) registry patients fulfilled all trial inclusion and exclusion criteria. Registry patients that would have been eligible for the RCTs were more often male, had higher eGFR values, higher rates of albuminuria, more received metformin, and more SGLT-2 inhibitors than patients that would not be eligible.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Certain patient subgroups, especially non-albuminuric CKD-patients, were not included in the RCTs. Although recommended by guidelines, there was an undertreatment of CKD-patients with renin-angiotensin system (RAS) blockers. Further research into patients with normoalbuminuric CKD and a wider prescription of RAS blocking agents for CKD patients in clinical practice appears warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01840-5","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T12:04:24Z","timestamp":1683547464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria"],"prefix":"10.1186","volume":"22","author":[{"given":"Peter","family":"Bramlage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Lanzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"M\u00fchldorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Milek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Veith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Danne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard W.","family":"Holl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Seufert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"issue":"3","key":"1840_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","volume":"94","author":"Y Xie","year":"2018","unstructured":"Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai CY, Floyd T, Al-Aly Z. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567\u201381.","journal-title":"Kidney Int"},{"issue":"1","key":"1840_CR2","first-page":"49","volume":"5","author":"O Gheith","year":"2016","unstructured":"Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5(1):49\u201356.","journal-title":"J Nephropharmacol"},{"key":"1840_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/1756-0500-7-415","volume":"7","author":"RA Bailey","year":"2014","unstructured":"Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on kidney disease: improving global outcomes (KDIGO) staging. BMC Res Notes. 2014;7:415.","journal-title":"BMC Res Notes"},{"issue":"12","key":"1840_CR4","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1840_CR5","doi-asserted-by":"publisher","first-page":"e0147329","DOI":"10.1371\/journal.pone.0147329","volume":"11","author":"M Narres","year":"2016","unstructured":"Narres M, Claessen H, Droste S, Kvitkina T, Koch M, Kuss O, Icks A. The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: a systematic review. PLoS ONE. 2016;11(1):e0147329.","journal-title":"PLoS ONE"},{"issue":"3","key":"1840_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jdiacomp.2017.12.003","volume":"32","author":"GA Nichols","year":"2018","unstructured":"Nichols GA, Deruaz-Luyet A, Hauske SJ, Brodovicz KG. The association between estimated glomerular filtration rate, albuminuria, and risk of cardiovascular hospitalizations and all-cause mortality among patients with type 2 diabetes. J Diabetes Complicat. 2018;32(3):291\u20137.","journal-title":"J Diabetes Complicat"},{"issue":"6","key":"1840_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41581-018-0001-y","volume":"14","author":"HJ Anders","year":"2018","unstructured":"Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361\u201377.","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"1840_CR8","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"1840_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"issue":"6","key":"1840_CR10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"P Gaede","year":"2008","unstructured":"Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580\u201391.","journal-title":"N Engl J Med"},{"issue":"20","key":"1840_CR11","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993;329(20):1456\u201362.","journal-title":"N Engl J Med."},{"issue":"2","key":"1840_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"24","key":"1840_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"1840_CR14","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"9","key":"1840_CR15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3(9):486\u201392.","journal-title":"Nat Clin Pract Nephrol"},{"issue":"2","key":"1840_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","volume":"51","author":"AS Bomback","year":"2008","unstructured":"Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008;51(2):199\u2013211.","journal-title":"Am J Kidney Dis"},{"key":"1840_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000503713","volume":"50","author":"GL Bakris","year":"2019","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50:1\u201312.","journal-title":"Am J Nephrol"},{"key":"1840_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000503712","volume":"50","author":"LM Ruilope","year":"2019","unstructured":"Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol. 2019;50:1\u201312.","journal-title":"Am J Nephrol"},{"issue":"23","key":"1840_CR19","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"1840_CR20","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"key":"1840_CR21","first-page":"1","volume":"00","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2021;00:1\u201312.","journal-title":"Eur Heart J"},{"issue":"1","key":"1840_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-019-0837-x","volume":"18","author":"P Bramlage","year":"2019","unstructured":"Bramlage P, Lanzinger S, van Mark G, Hess E, Fahrner S, Heyer CHJ, Friebe M, Seufert J, Danne T, Holl RW. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases. Cardiovasc Diabetol. 2019;18(1):33.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1840_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12882-021-02394-y","volume":"22","author":"P Bramlage","year":"2021","unstructured":"Bramlage P, Lanzinger S, Tittel SR, Hess E, Fahrner S, Heyer CHJ, Friebe M, Buschmann I, Danne T, Seufert J, et al. Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations\u2014a registry-based analysis. BMC Nephrol. 2021;22(1):184.","journal-title":"BMC Nephrol"},{"key":"1840_CR24","unstructured":"Diabetes-Patienten-Verlaufsdokumentation (DPV) [http:\/\/buster.zibmt.uni-ulm.de\/dpv\/index.php\/en\/]."},{"issue":"6","key":"1840_CR25","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.jpeds.2015.09.006","volume":"167","author":"KO Schwab","year":"2015","unstructured":"Schwab KO, Doerfer J, Hungele A, Scheuing N, Krebs A, Dost A, Rohrer TR, Hofer S, Holl RW. Non-high-density lipoprotein cholesterol in children with diabetes: proposed treatment recommendations based on glycemic control, body mass index, age, sex, and generally accepted cut points. J Pediatr. 2015;167(6):1436\u20139.","journal-title":"J Pediatr"},{"issue":"1","key":"1840_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12933-016-0391-8","volume":"15","author":"B Bohn","year":"2016","unstructured":"Bohn B, Schofl C, Zimmer V, Hummel M, Heise N, Siegel E, Karges W, Riedl M, Holl RW, initiative DPV. Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German\/Austrian DPV-multicenter analysis. Cardiovasc Diabetol. 2016;15(1):72.","journal-title":"Cardiovasc Diabetol"},{"issue":"18","key":"1840_CR27","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1055\/s-0033-1343144","volume":"138","author":"T Danne","year":"2013","unstructured":"Danne T, Kaltheuner M, Koch A, Ernst S, Rathmann W, Russmann HJ, Bramlage P, Studiengruppe D. \u201cDIabetes Versorgungs-evaluation\u201d (DIVE)\u2013a national quality assurance initiative at physicians providing care for patients with diabetes. Dtsch Med Wochenschr. 2013;138(18):934\u20139.","journal-title":"Dtsch Med Wochenschr"},{"issue":"1","key":"1840_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"AS Levey","year":"2011","unstructured":"Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int. 2011;80(1):17\u201328.","journal-title":"Kidney Int"},{"key":"1840_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/kisup.2012.64","volume":"3","author":"KDIGO 2012","year":"2013","unstructured":"KDIGO 2012. Clinical practice guideline for the evaluation and management of chronic kidney disease: chapter 1: definition and classification of CKD. Kidney Int Suppl. 2013;3:19\u201362.","journal-title":"Kidney Int Suppl"},{"issue":"9","key":"1840_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jdiacomp.2017.06.016","volume":"31","author":"A Schwandt","year":"2017","unstructured":"Schwandt A, Denkinger M, Fasching P, Pfeifer M, Wagner C, Weiland J, Zeyfang A, Holl RW. Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes. J Diabetes Complicat. 2017;31(9):1376\u201383.","journal-title":"J Diabetes Complicat"},{"issue":"25","key":"1840_CR31","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"group Sw","year":"2021","unstructured":"group Sw, collaboration ESCCr. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439\u201354.","journal-title":"Eur Heart J."},{"issue":"10","key":"1840_CR32","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/sj.ki.5001794","volume":"70","author":"MW Taal","year":"2006","unstructured":"Taal MW, Brenner BM. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int. 2006;70(10):1694\u2013705.","journal-title":"Kidney Int"},{"issue":"1","key":"1840_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1365-2125.2003.01953.x","volume":"57","author":"K Martin","year":"2004","unstructured":"Martin K, Begaud B, Latry P, Miremont-Salame G, Fourrier A, Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol. 2004;57(1):86\u201392.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1840_CR34","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1111\/jgs.14833","volume":"65","author":"FT Bourgeois","year":"2017","unstructured":"Bourgeois FT, Orenstein L, Ballakur S, Mandl KD, Ioannidis JPA. Exclusion of elderly people from randomized clinical trials of drugs for ischemic heart disease. J Am Geriatr Soc. 2017;65(11):2354\u201361.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"1840_CR35","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/jgs.12215","volume":"61","author":"AJ Cruz-Jentoft","year":"2013","unstructured":"Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquin B, Sanchez-Castellano C, Sanchez-Garcia E. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc. 2013;61(5):734\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"1840_CR36","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/healthcare9050580","volume":"9","author":"YT Li","year":"2021","unstructured":"Li YT, Wang Y, Hu XJ, Chen JH, Li YY, Zhong QY, Cheng H, Mohammed BH, Liang XL, Hernandez J, et al. Association between systolic blood pressure and diabetic retinopathy in both hypertensive and normotensive patients with type 2 diabetes: risk factors and healthcare implications. Healthcar. 2021;9(5):580.","journal-title":"Healthcar"},{"issue":"20","key":"1840_CR37","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, Devore AD, Yancy CW, Fonarow GC. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476\u201386.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1840_CR38","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1056\/NEJMsa035507","volume":"349","author":"C Lenfant","year":"2003","unstructured":"Lenfant C. Shattuck lecture\u2013clinical research to clinical practice\u2013lost in translation? N Engl J Med. 2003;349(9):868\u201374.","journal-title":"N Engl J Med"},{"issue":"11","key":"1840_CR39","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825\u201330.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1840_CR40","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1681\/ASN.2008121270","volume":"20","author":"T Ninomiya","year":"2009","unstructured":"Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813\u201321.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"1840_CR41","doi-asserted-by":"publisher","first-page":"e025079","DOI":"10.1161\/JAHA.121.025079","volume":"11","author":"N Chiu","year":"2022","unstructured":"Chiu N, Aggarwal R, Bakris GL, Pitt B, Bhatt DL. Generalizability of FIGARO-DKD and FIDELIO-DKD trial criteria to the US population eligible for finerenone. J Am Heart Assoc. 2022;11(7):e025079.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"1840_CR42","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.3390\/ijms22115425","volume":"22","author":"D Santoro","year":"2021","unstructured":"Santoro D, Torreggiani M, Pellicano V, Cernaro V, Messina RM, Longhitano E, Siligato R, Gembillo G, Esposito C, Piccoli GB. Kidney biopsy in type 2 diabetic patients: critical reflections on present indications and diagnostic alternatives. Int J Mol Sci. 2021;22(11):5425.","journal-title":"Int J Mol Sci"},{"issue":"Suppl 2","key":"1840_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2337\/diab.32.2.S64","volume":"32","author":"CE Mogensen","year":"1983","unstructured":"Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64\u201378.","journal-title":"Diabetes"},{"issue":"1","key":"1840_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40620-019-00650-x","volume":"33","author":"G Pugliese","year":"2020","unstructured":"Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G, Gesualdo L, De Nicola L, Italian Diabetes S, the Italian Society of N. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian diabetes society and the Italian Society of Nephrology on \u201cThe natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function.\u201d J Nephrol. 2020;33(1):9\u201335.","journal-title":"J Nephrol"},{"issue":"6","key":"1840_CR45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000484633","volume":"46","author":"MJ Jardine","year":"2017","unstructured":"Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, et al. The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol. 2017;46(6):462\u201372.","journal-title":"Am J Nephrol"},{"issue":"10","key":"1840_CR46","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","volume":"35","author":"DC Wheeler","year":"2020","unstructured":"Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020;35(10):1700\u201311.","journal-title":"Nephrol Dial Transplant"},{"key":"1840_CR47","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","volume":"37","author":"Group E-KC","year":"2022","unstructured":"Group E-KC. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2022;37:1317.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1840_CR48","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/MAJ.0000000000000475","volume":"349","author":"S Shirazian","year":"2015","unstructured":"Shirazian S, Grant CD, Mujeeb S, Sharif S, Kumari P, Bhagat M, Mattana J. Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease. Am J Med Sci. 2015;349(6):510\u20135.","journal-title":"Am J Med Sci"},{"issue":"1","key":"1840_CR49","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.clinthera.2014.11.011","volume":"37","author":"KB Sonawane","year":"2015","unstructured":"Sonawane KB, Qian J, Hansen RA. Utilization patterns of antihypertensive drugs among the chronic kidney disease population in the United States: a cross-sectional analysis of the national health and nutrition examination survey. Clin Ther. 2015;37(1):188\u201396.","journal-title":"Clin Ther"},{"issue":"6","key":"1840_CR50","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1053\/j.ajkd.2009.02.013","volume":"53","author":"AM O'Hare","year":"2009","unstructured":"O\u2019Hare AM. The management of older adults with a low eGFR: moving toward an individualized approach. Am J Kidney Dis. 2009;53(6):925\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1840_CR51","doi-asserted-by":"publisher","first-page":"742","DOI":"10.34067\/KID.0000412021","volume":"2","author":"D Lam","year":"2021","unstructured":"Lam D, Shaikh A. Real-life prescribing of sglt2 inhibitors: how to handle the other medications including glucose-lowering drugs and diuretics. Kidney 360. 2021;2(4):742\u20136.","journal-title":"Kidney 360"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01840-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T13:09:16Z","timestamp":1683551356000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01840-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1840"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01840-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"9 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The DPV initiative, which was established in 1995, was approved by the ethics committee of the University of Ulm, and data collection was approved by local review boards. The DIVE registry was established in Germany in 2011. The protocol was approved by the ethics committee of the Medical School of Hannover, and all patients included in the DIVE registry provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JS and TD report Grants and personal fees from Abbott, AstraZeneca, and Sanofi, outside the submitted work. PB reports to have received research support from the funders of DIVE. SL, SM, KM, AG, RV, TO and RWH have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}